These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29226173)

  • 21. Antiretroviral treatment uptake in patients with HIV-associated TB attending co-located TB and ART services.
    Nglazi MD; Kaplan R; Caldwell J; Peton N; Lawn SD; Wood R; Bekker LG
    S Afr Med J; 2012 Oct; 102(12):936-9. PubMed ID: 23498041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence of tuberculosis among HIV infected individuals on long term antiretroviral therapy in private healthcare sector in Pune, Western India.
    Dravid A; Natarajan K; Medisetty M; Gawali R; Mahajan U; Kulkarni M; Saraf C; Ghanekar C; Kore S; Rathod N; Dravid M
    BMC Infect Dis; 2019 Aug; 19(1):714. PubMed ID: 31409289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD4 count at antiretroviral therapy initiation and the risk of loss to follow-up: results from a multicentre cohort study.
    Grimsrud A; Cornell M; Schomaker M; Fox MP; Orrell C; Prozesky H; Stinson K; Tanser F; Egger M; Myer L;
    J Epidemiol Community Health; 2016 Jun; 70(6):549-55. PubMed ID: 26700300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community.
    Gupta A; Wood R; Kaplan R; Bekker LG; Lawn SD
    PLoS One; 2012; 7(3):e34156. PubMed ID: 22479548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimating loss to follow-up in HIV-infected patients on antiretroviral therapy: the effect of the competing risk of death in Zambia and Switzerland.
    Schöni-Affolter F; Keiser O; Mwango A; Stringer J; Ledergerber B; Mulenga L; Bucher HC; Westfall AO; Calmy A; Boulle A; Chintu N; Egger M; Chi BH; ;
    PLoS One; 2011; 6(12):e27919. PubMed ID: 22205933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control.
    Lawn SD; Myer L; Bekker LG; Wood R
    AIDS; 2006 Aug; 20(12):1605-12. PubMed ID: 16868441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of the interval between the initiation of antiretroviral therapy and the initiation of anti-tuberculosis treatment in HIV/tuberculosis-coinfected patients: results from the TREAT Asia HIV Observational Database.
    Han SH; Zhou J; Lee MP; Zhao H; Chen YM; Kumarasamy N; Pujari S; Lee C; Omar SF; Ditangco R; Phanuphak N; Kiertiburanakul S; Chaiwarith R; Merati TP; Yunihastuti E; Tanuma J; Saphonn V; Sohn AH; Choi JY;
    HIV Med; 2014 Feb; 15(2):77-85. PubMed ID: 23980589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retention in care among HIV-positive patients initiating second-line antiretroviral therapy: a retrospective study from an Ethiopian public hospital clinic.
    Wilhelmson S; Reepalu A; Balcha TT; Jarso G; Björkman P
    Glob Health Action; 2016; 9():29943. PubMed ID: 26765104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment outcomes of HIV-infected adolescents attending public-sector HIV clinics across Gauteng and Mpumalanga, South Africa.
    Evans D; Menezes C; Mahomed K; Macdonald P; Untiedt S; Levin L; Jaffray I; Bhana N; Firnhaber C; Maskew M
    AIDS Res Hum Retroviruses; 2013 Jun; 29(6):892-900. PubMed ID: 23373540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Opportunistic diseases diminish the clinical benefit of immediate antiretroviral therapy in HIV-tuberculosis co-infected adults with low CD4+ cell counts.
    Worodria W; Ssempijja V; Hanrahan C; Ssegonja R; Muhofwa A; Mazapkwe D; Mayanja-Kizza H; Reynolds SJ; Colebunders R; Manabe YC
    AIDS; 2018 Sep; 32(15):2141-2149. PubMed ID: 30005014
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determine TB-LAM point-of-care tuberculosis assay predicts poor outcomes in outpatients during their first year of antiretroviral therapy in South Africa.
    Kerkhoff AD; Longley N; Kelly N; Cross A; Vogt M; Wood R; Hermans S; Lawn SD; Harrison TS
    BMC Infect Dis; 2020 Jul; 20(1):555. PubMed ID: 32736601
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determinants of loss to follow-up among HIV positive patients receiving antiretroviral therapy in a test and treat setting: A retrospective cohort study in Masaka, Uganda.
    Kiwanuka J; Mukulu Waila J; Muhindo Kahungu M; Kitonsa J; Kiwanuka N
    PLoS One; 2020; 15(4):e0217606. PubMed ID: 32255796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tuberculosis associated mortality in a prospective cohort in Sub Saharan Africa: Association with HIV and antiretroviral therapy.
    Nagu TJ; Aboud S; Mwiru R; Matee MI; Rao M; Fawzi WW; Zumla A; Maeurer MJ; Mugusi F
    Int J Infect Dis; 2017 Mar; 56():39-44. PubMed ID: 28161460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug Resistance in HIV-Positive Adults During the Initial Year of Antiretroviral Treatment at Ethiopian Health Centers.
    Reepalu A; Arimide DA; Balcha TT; Yeba H; Zewdu A; Medstrand P; Björkman P
    Open Forum Infect Dis; 2021 Apr; 8(4):ofab106. PubMed ID: 34805444
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected clients under pre-ART care, Jimma, Ethiopia: a retrospective cohort study.
    Assebe LF; Reda HL; Wubeneh AD; Lerebo WT; Lambert SM
    BMC Public Health; 2015 Apr; 15():346. PubMed ID: 25886730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ten year experience with antiretroviral treatment in Cambodia: Trends in patient characteristics and treatment outcomes.
    Lay P; An S; Soeung S; Srey PS; Thai S; Lynen L; Griensven JV
    PLoS One; 2017; 12(11):e0185348. PubMed ID: 29136011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa.
    Lawn SD; Myer L; Edwards D; Bekker LG; Wood R
    AIDS; 2009 Aug; 23(13):1717-25. PubMed ID: 19461502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tuberculosis incidence rate and risk factors among HIV-infected adults with access to antiretroviral therapy.
    Liu E; Makubi A; Drain P; Spiegelman D; Sando D; Li N; Chalamilla G; Sudfeld CR; Hertzmark E; Fawzi WW
    AIDS; 2015 Jul; 29(11):1391-9. PubMed ID: 26091295
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence and predictors of tuberculosis occurrence among adults on antiretroviral therapy at Debre Markos referral hospital, Northwest Ethiopia: retrospective follow-up study.
    Aemro A; Jember A; Anlay DZ
    BMC Infect Dis; 2020 Mar; 20(1):245. PubMed ID: 32216747
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.